Amedeo Smart

Free Medical Literature Service



Hepatitis C

  Free Subscription

Articles published in
J Infect Dis
    May 2024
  1. MBISA JL, Lapp Z, Bibby DF, Phillips LT, et al
    Identification of two novel subtypes of hepatitis C virus genotype 8 and a potential new genotype successfully treated with direct acting antivirals.
    J Infect Dis. 2024 May 8:jiae253. doi: 10.1093.
    >> Share

    April 2024
  2. SELVAMANI SP, Khan A, Tay ESE, Garvey M, et al
    Hepatitis B virus and hepatitis C virus affect mitochondrial function through different metabolic pathways, explaining virus-specific clinical features of chronic hepatitis.
    J Infect Dis. 2024 Apr 24:jiae210. doi: 10.1093.
    >> Share

    March 2024
  3. WHITTAKER R, Midtbo JE, Klovstad H
    Monitoring progress towards the elimination of hepatitis C as a public health threat in Norway: a modelling study among people who inject drugs and immigrants.
    J Infect Dis. 2024 Mar 27:jiae147. doi: 10.1093.
    >> Share

  4. KAMILI S, Wester C
    Advancing diagnosis of current HCV infection: A key to hepatitis C elimination in the United States.
    J Infect Dis. 2024 Mar 11:jiae127. doi: 10.1093.
    >> Share

  5. ASLANIKASHVILI A, Rylander C, Manjavidze T, Gamkrelidze A, et al
    Relationship between hepatitis C infection and treatment status and COVID-19-related hospitalizations in Georgia.
    J Infect Dis. 2024 Mar 1:jiae103. doi: 10.1093.
    >> Share

    February 2024
  6. TU T, Ajoyan H, Nur Umami R, Veeraraghavan V, et al
    Inhibition of cellular factor TM6SF2 suppresses secretion pathways of Hepatitis B, Hepatitis C and Hepatitis D viruses.
    J Infect Dis. 2024 Feb 26:jiae098. doi: 10.1093.
    >> Share

    October 2023
  7. IVANOVA REIPOLD E, Shilton S, Donolato M, Fernandez Suarez M, et al
    Molecular point of care testing for hepatitis C: available technologies, pipeline and promising future directions.
    J Infect Dis. 2023 Oct 28:jiad463. doi: 10.1093.
    >> Share

  8. FELD JJ
    What is needed to move toward single-step diagnosis of current HCV infection?
    J Infect Dis. 2023 Oct 13:jiad453. doi: 10.1093.
    >> Share

  9. FALADE-NWULIA O, Lesko CR, Fojo AT, Keruly JC, et al
    Hepatitis C treatment in people living with HIV: Potential to eliminate disease and disparity.
    J Infect Dis. 2023 Oct 5:jiad433. doi: 10.1093.
    >> Share

    September 2023
  10. FRICKER GP, Ghany MG, Mera J, Pinsky BA, et al
    Tools Needed to Support Same-day Diagnosis and Treatment of Current Hepatitis C Infection.
    J Infect Dis. 2023 Sep 22:jiad177. doi: 10.1093.
    >> Share

    Opportunities for enhanced prevention and control of hepatitis C through improved screening and testing efforts.
    J Infect Dis. 2023 Sep 22:jiad199. doi: 10.1093.
    >> Share

  12. JOHNSON LN, Gaynor AM, Wroblewski K, Buss SN, et al
    Maximizing Reflexive HCV RNA Testing of HCV Antibody-Reactive Samples Within United States Public Health Laboratories.
    J Infect Dis. 2023 Sep 22:jiad191. doi: 10.1093.
    >> Share

    Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis.
    J Infect Dis. 2023 Sep 22:jiad299. doi: 10.1093.
    >> Share

  14. PAGE K, Feinberg J
    What Hepatitis C (HCV) diagnostic tools are needed to advance diagnosis of current HCV infection in outreach settings and in a non-clinical setting?
    J Infect Dis. 2023 Sep 22:jiad269. doi: 10.1093.
    >> Share

  15. HANDANAGIC S, Shadaker S, Drobeniuc J, Tsereteli M, et al
    Lessons learned from global hepatitis C elimination programs.
    J Infect Dis. 2023 Sep 22:jiad198. doi: 10.1093.
    >> Share

  16. CHIEN RN, Lu SN, Hui-Min Wu G, Yang WW, et al
    Policy and Strategy for Hepatitis C Virus Elimination at the National Level: Experience in Taiwan.
    J Infect Dis. 2023;228.
    >> Share

  17. KONDILI LA, Craxi L, Nava F, Babudieri S, et al
    From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy.
    J Infect Dis. 2023;228.
    >> Share

  18. AARON A, Zhong H, Hiebert L, Zhuo Y, et al
    Hepatitis C Elimination in Moldova Is Feasible and Cost-Saving: A Modeling Study.
    J Infect Dis. 2023;228.
    >> Share

  19. WASITTHANKASEM R, Wanlapakorn N, Pimsing N, Posuwan N, et al
    Simplified Test-to-Treat Strategy for Hepatitis C in Thailand: The Phetchabun Model.
    J Infect Dis. 2023;228.
    >> Share

    Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.
    J Infect Dis. 2023;228.
    >> Share

  21. HUANG CF, Chen GJ, Hung CC, Yu ML, et al
    HCV Microelimination for High-risk Special Populations.
    J Infect Dis. 2023;228.
    >> Share

  22. ADDA D, James C, Peck R, Ali M, et al
    The Role of Nonprofit and Nongovernmental Organizations and People With Viral Hepatitis on the Path Toward Hepatitis C Virus Elimination.
    J Infect Dis. 2023;228.
    >> Share

  23. UMUTESI J, Yu ML, Lesi O, Ward JW, et al
    Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan Africa.
    J Infect Dis. 2023;228.
    >> Share

  24. SPAULDING AC, Kennedy SS, Osei J, Sidibeh E, et al
    Estimates of Hepatitis C Seroprevalence and Viremia in State Prison Populations in the United States.
    J Infect Dis. 2023;228.
    >> Share

  25. QURESHI H, Mahmood H, Sabry A, Hermez J, et al
    Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
    J Infect Dis. 2023;228.
    >> Share

    July 2023
  26. POWELL JG, Goble SR, Debes JD
    Re-vaccination For Hepatitis B in Previous Non-Responders Following Hepatitis C Eradication.
    J Infect Dis. 2023 Jul 31:jiad301. doi: 10.1093.
    >> Share

  27. FIERER DS, Schinkel J
    Redefining the Paradigm: The Role of Sexual Networks and Sexualized Drug Use in the Transmission of HCV Among Men Who Have Sex with Men.
    J Infect Dis. 2023 Jul 24:jiad265. doi: 10.1093.
    >> Share

    June 2023
  28. ARTENIE A, Stone J, Facente SN, Fraser H, et al
    Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis.
    J Infect Dis. 2023 Jun 24:jiad169. doi: 10.1093.
    >> Share

    March 2023
  29. GAMKRELIDZE A, Shadaker S, Tsereteli M, Alkhazashvili M, et al
    Nationwide hepatitis C serosurvey and progress towards HCV elimination in the country of Georgia, 2021.
    J Infect Dis. 2023 Mar 18:jiad064. doi: 10.1093.
    >> Share

    February 2023
  30. SACHITHANANDHAM J, Balagopal A, Leep-Lazar J, Quinn J, et al
    Second-phase hepatitis C plasma viral kinetics directly reflects reduced intrahepatic burden of HCV.
    J Infect Dis. 2023 Feb 1:jiad025. doi: 10.1093.
    >> Share

    October 2022
  31. MILLER-ARCHIE SA, Walters SC, Bocour A, Moore MS, et al
    The Impact of Supportive Housing on Liver-Related Outcomes Among Persons With Hepatitis C Virus Infection.
    J Infect Dis. 2022;226.
    >> Share

    August 2022
  32. VETTER BN, Reipold EI, Ongarello S, Audu R, et al
    Sensitivity and Specificity of Rapid Diagnostic Tests for Hepatitis C Virus With or Without HIV Coinfection: A Multicentre Laboratory Evaluation Study.
    J Infect Dis. 2022;226:420-430.
    >> Share

  33. OGAWA E, Nomura H, Nakamuta M, Furusyo N, et al
    Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
    J Infect Dis. 2022;226:431-440.
    >> Share

  34. KITABAYASHI J, Shirasaki T, Shimakami T, Nishiyama T, et al
    Upregulation of the Long Noncoding RNA HULC by Hepatitis C Virus and Its Regulation of Viral Replication.
    J Infect Dis. 2022;226:407-419.
    >> Share

  35. GARDNER AR, Ma Y, Bacchetti P, Price JC, et al
    Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment.
    J Infect Dis. 2022 Aug 11. pii: 6650396. doi: 10.1093.
    >> Share

    February 2022
  36. CATLETT B, Hajarizadeh B, Cunningham E, Wolfson-Stofko B, et al
    Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of HCV RNA: a systematic review.
    J Infect Dis. 2022 Feb 12. pii: 6527696. doi: 10.1093.
    >> Share

    September 2021
  37. WARD KM, Falade-Nwulia O, Moon J, Sutcliffe CG, et al
    Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs.
    J Infect Dis. 2021 Sep 20. pii: 6372878. doi: 10.1093.
    >> Share

    June 2021
  38. NDOW G, Cessay A, Cohen D, Shimakawa Y, et al
    Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa.
    J Infect Dis. 2021 Jun 23. pii: 6308183. doi: 10.1093.
    >> Share

    March 2021
  39. ARANDAY-CORTES E, McClure CP, Davis C, Irving WL, et al
    Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa.
    J Infect Dis. 2021 Mar 1. pii: 6154708. doi: 10.1093.
    >> Share

    February 2021
  40. CHUAYPEN N, Jinato T, Avihingsanon A, Chirapongsathorn S, et al
    Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection.
    J Infect Dis. 2021 Feb 17. pii: 6141513. doi: 10.1093.
    >> Share

    January 2021
  41. KHERA T, Du Y, Todt D, Deterding K, et al
    Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C.
    J Infect Dis. 2021 Jan 31. pii: 6124746. doi: 10.1093.
    >> Share

    November 2020
  42. JEYARAJAN AJ, Chung RT
    Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?
    J Infect Dis. 2020;222.
    >> Share

  43. BAJIS S, Applegate TL, Grebely J, Matthews GV, et al
    Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic.
    J Infect Dis. 2020;222.
    >> Share

  44. CHAPPELL CA, Jonas MM
    Hepatitis C Virus in Pregnancy: Are We Ready for Test and Treat?
    J Infect Dis. 2020;222.
    >> Share

    30 Years on the Road to Hepatitis C Elimination.
    J Infect Dis. 2020;222.
    >> Share

  46. NAGGIE S, Wyles D
    Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination.
    J Infect Dis. 2020;222.
    >> Share

  47. FALADE-NWULIA O, Sulkowski MS
    Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.
    J Infect Dis. 2020;222.
    >> Share

  48. TROOSKIN SB, Dore G, Kostman J
    We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States.
    J Infect Dis. 2020;222.
    >> Share

  49. ROCKSTROH JK, Boesecke C
    Hepatitis C Virus Treatment as Prevention: Challenges and Opportunities in Men Who Have Sex With Men.
    J Infect Dis. 2020;222.
    >> Share

  50. KAPPUS MR, Wolfe CR, Muir AJ
    Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?
    J Infect Dis. 2020;222.
    >> Share

  51. HALEY DF, Edmonds A, Ramirez C, French AL, et al
    Direct-acting antiviral Hepatitis C treatment cascade and barriers to treatment initiation among US men and women with and without HIV.
    J Infect Dis. 2020 Nov 3. pii: 5952700. doi: 10.1093.
    >> Share

    October 2020
  52. VERGARA C, Valencia A, Thio CL, Goedert JJ, et al
    A multi-ancestry sex stratified genome-wide association study of spontaneous clearance of hepatitis C virus.
    J Infect Dis. 2020 Oct 29. pii: 5943036. doi: 10.1093.
    >> Share

    Hepatitis C virus vaccine development: A step forward.
    J Infect Dis. 2020 Oct 11. pii: 5920711. doi: 10.1093.
    >> Share

    September 2020
  54. SPRINGER SA, Barocas JA, Wurcel A, Nijhawan A, et al
    Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.
    J Infect Dis. 2020;222.
    >> Share

  55. ROWAN SE, Kamis KF, Beum R, Bryan K, et al
    Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program.
    J Infect Dis. 2020;222.
    >> Share

    August 2019
  56. KOSLOSKI MP, Oberoi R, Wang S, Viani RM, et al
    Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered with Human Immunodeficiency Virus Antiretrovirals.
    J Infect Dis. 2019 Aug 29. pii: 5556482. doi: 10.1093.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016